Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive Treatment (RIAltO)

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2012 by University of Liverpool
Sponsor:
Collaborators:
GlaxoSmithKline
Napp Pharmaceuticals Limited
Chugai Pharma USA
Information provided by:
University of Liverpool
ClinicalTrials.gov Identifier:
NCT01678430
First received: August 30, 2012
Last updated: October 12, 2012
Last verified: August 2012
  Purpose

The purpose of this study is to compare ofatumumab & chlorambucil (O-Chl) versus ofatumumab & bendamustine (O-B) in patients with Chronic Lymphocytic Leukaemia who are considered not fit enough for rituximab, fludarabine & cyclophosphamide (R-FC).


Condition Intervention Phase
Chronic Lymphocytic Leukaemia
Drug: Ofatumumab
Drug: Chlorambucil
Drug: Bendamustine
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Randomised Investigation of Alternative Ofatumumab-containing Regimens in Less Fit Patients With CLL

Resource links provided by NLM:


Further study details as provided by University of Liverpool:

Primary Outcome Measures:
  • Progression-free survival [ Time Frame: There are three pre-planned analyses of the PFS primary endpoint: end recruitment (approx 150 events); 300 events (after a minimum 12 months follow up for all patients), 400 events (after a minimum 24 months follow up for all patients) ] [ Designated as safety issue: No ]
    Calculated from the date of randomisation to the date of progression or death, or the censor date.


Secondary Outcome Measures:
  • Duration of response [ Time Frame: 6 years (after 2 years follow up of the last patient recruited) ] [ Designated as safety issue: No ]
    Response duration is defined as the time from when the criteria for partial or complete response are met until the first documentation of relapse or progression.

  • Overall survival [ Time Frame: 6 years (after 2 year follow up of the last patient recruited) ] [ Designated as safety issue: No ]
    Overall survival is defined as the time from initiation of study treatment to death, irrespective of cause or subsequent treatment. Patients still alive at the time of analysis will be censored at the date last seen alive at last follow up.

  • Time to treatment failure [ Time Frame: 6 years (after 2 year follow up of the last patient recruited) ] [ Designated as safety issue: No ]
    Time to treatment failure is defined as the time from initiation of study treatment to death, disease progression, or initiation of alternative treatment due to failure to achieve a complete or partial response to the study treatment.

  • Toxicity [ Time Frame: 6 years (after 2 years follow up of the last patient recruited) ] [ Designated as safety issue: Yes ]
    Haematological toxicity will be reported in accordance with the 2008 NCI/IWCLL guidelines. Non-haematological toxicity will be reported in accordance with the current Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0.

  • Treatment dose administered [ Time Frame: 5 years (assuming last patient in receives 12 cycles of treatment) ] [ Designated as safety issue: No ]
    The number of cycles of treatment and cumulative dose of individual drugs administered will be summarised for each treatment group separately and compared across treatment groups

  • Quality of life [ Time Frame: 6 years (after 2 years follow up of the last patient recruited) ] [ Designated as safety issue: No ]
    Quality of life will be assessed using the EQ-5D; EQ-VAS; EORTC QLQ-C30 and EORTC QLQ-CLL16 questionnaires. To standardise the raw scores, they will be linearly transformed into 0-to-100 scores.

  • Health Economic analysis [ Time Frame: 6 years (after 2 years follow up of the last patient recruited) ] [ Designated as safety issue: No ]

    The economic evaluation will take the form of a cost-effectiveness analysis with the differential cost of the alternative treatments will be related to their differential benefits in terms of quality-adjusted life years (QALYs). Incremental cost-utility ratios will be estimated based on QALY estimates.

    A range of uni- and multi-variate, as well as probabilistic sensitivity analyses will be conducted to assess the robustness of the analysis.

    The use of bootstrapping and cost-effectiveness acceptability curves will facilitate a measure of variability around cost-effectiveness estimates. Sensitivity analysis will be used to consider the importance of sources of uncertainty other than sample variation (e.g. unit costs, discount rates).

    A model-based extrapolation of the trial results will be performed to explore the impact of a longer analytic time horizon, and consideration of health outcomes on the treatment cost-effectiveness.


  • Analysis of frailty and co-morbidity [ Time Frame: Baseline, 2 months post treatment ] [ Designated as safety issue: No ]
    Patients outcomes will be compared across patient subgroups defined by CIRS, performance status, Vulnerable Elders Survey-13, Groningen Frailty Index (GFI) questionnaires and the Timed 'Up and Go' test.

  • Predictive value of biomarkers [ Time Frame: Baseline, every 6 months until 42 months from study entry, disease progression ] [ Designated as safety issue: No ]
    Patient outcomes will be compared across patient subgroups defined by clinical (e.g. age, sex, stage) and laboratory (e.g. chromosomal, abnormalities, IGHV mutation status, TP53 mutation status).

  • Response [ Time Frame: Baseline; 2 months post treatment; 6 months post treatment ] [ Designated as safety issue: No ]
    Response following initial therapy will be assessed in accordance with the revised (2008) NCI/IWCLL response criteria applicable to CLL. Minimal residual disease will be assessed by multicolour flow cytometric analysis of bone marrow aspirate samples taken 2 months after completing treatment and of blood samples taken 2 and 6 months after completing treatment.


Estimated Enrollment: 670
Study Start Date: December 2011
Estimated Study Completion Date: December 2017
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Ofatumumab-Chlorambucil
Ofatumumab cycle 1: 300mg iv day 1, 1000mg iv day 8; cycle 2 onwards: 1000mg iv day 1 Chlorambucil: 10mg/m2 po days 1-7
Drug: Ofatumumab
Other Name: Arzerra
Drug: Chlorambucil
Other Name: Leukeran
Experimental: Ofatumumab-Bendamustine
Ofatumumab cycle 1: 300mg iv day 1, 1000mg iv day 8; cycle 2 onwards: 1000mg iv day 1 Bendamustine: 70mg/m2 iv days 1 and 2
Drug: Ofatumumab
Other Name: Arzerra
Drug: Bendamustine
Other Name: Levact

Detailed Description:

Chlorambucil (Chl) has been the mainstay of CLL treatment for half a century. However, frontline treatment has improved considerably over the last decade, first by the advent of fludarabine plus cyclophosphamide (FC), and more recently by the addition of the anti-CD20 antibody, rituximab, to FC. Although FC-based regimens are considerably more effective than Chl, they are also associated with greater toxicity which makes them inappropriate for less fit patients. This is an important consideration, given that CLL predominantly affects older people who tend to have more co-morbidity. Although a single-arm phase II study (Roche MO20927; NCRI CLL208) has shown that R-Chl is safe and effective, there are no phase III data proving the benefit of adding an anti-CD20 antibody to Chl. This question is currently being addressed by a phase III RCT of Chl with or without ofatumumab (GSK OMB110911 / COMPLEMENT-1 / NCRI CLL7). Ofatumumab is a fully human anti-CD20 antibody that binds to an epitope distinct from that of rituximab and produces more complement-dependent cytotoxicity. The RIAltO trial is a direct follow-on to the NCRI CLL7 phase III RCT trial in less fit patients and therefore the Ofatumumab dose has been selected to mirror the regimen used in that trial.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. CLL/SLL requiring treatment by NCI/IWCLL 2008 criteria. At least one of the following criteria:

    1. Progressive marrow failure as manifested by the development of, or worsening of, anaemia and/or thrombocytopenia.
    2. Massive (i.e. 6 cm below the left costal margin) or progressive or symptomatic splenomegaly.
    3. Massive (i.e. 10 cm in longest diameter) or progressive or symptomatic lymphadenopathy.
    4. Progressive lymphocytosis with an increase of more than 50% over a 2-month period or lymphocyte doubling time (LDT) of less than 6 months.
  2. No prior cytotoxic or targeted therapy for CLL
  3. Full-dose R-FC considered inappropriate for at least one of the following reasons

    1. Age 75 or greater
    2. WHO performance status 2 or 3
    3. Cardiac impairment (NYHA class II)
    4. Respiratory impairment (bronchiectasis or moderate COPD)
    5. Renal impairment (estimated Glomerular Filtration Rate (eGFR) 10-30 ml/min)
    6. Any other significant co-morbidity or factor that makes R-FC inappropriate
  4. Considered able to tolerate Chl at the dose used in the LRF CLL4 trial (10mg/m2 d1-7)
  5. Written informed consent

Exclusion Criteria:

  1. Neutrophil count less than 1.0 x 109/l or platelet count less than 50 x 109/l unless due to CLL
  2. Uncontrolled auto-immune haemolytic anaemia or thrombocytopenia
  3. Active infection
  4. Seropositivity for HIV, HCV or HBV (surface antigen or and core antibody)
  5. Severe renal impairment (eGFR less than 10ml/min)
  6. Severe hepatic impairment (serum bilirubin more than twice the upper limit of normal) unless due to CLL or Gilbert's syndrome.
  7. Concurrent treatment with glucocorticoids equivalent to more than prednisolone 20mg od
  8. Prior treatment with monoclonal antibody therapy within the last 3 months.
  9. Yellow fever vaccination within 4 weeks prior to treatment start
  10. Known hypersensitivity to ofatumumab, bendamustine or chlorambucil or any of their excipients
  11. CNS involvement with CLL
  12. History of Richter transformation
  13. Concomitant malignancies within the last 3 years except successfully treated non-melanoma skin cancer or carcinoma in situ.
  14. Major surgery within 28 days prior to randomisation
  15. WHO performance status 4
  16. Severe cardiac disease including unstable angina, acute myocardial infarction within six months prior to randomization, congestive heart failure (NYHA III-IV), and arrhythmia (excluding extra systoles or minor conduction abnormalities) unless controlled by therapy.
  17. Any serious underlying medical or psychological conditions, which could impair the ability of the patient to participate in the trial or compromise ability to give informed consent
  18. Treatment within a clinical trial within 30 days prior to trial entry.
  19. Adult patient under tutelage (not competent to sign informed consent).
  20. Pregnant or lactating women.
  21. Women of childbearing potential, including women whose last menstrual period was less than one year prior to screening, unable or unwilling to use adequate contraception from study start to one year after the last dose of protocol therapy. Adequate contraception is defined as hormonal birth control, intrauterine device, double barrier method or total abstinence.
  22. Male subjects unable or unwilling to use adequate contraception methods from study start to one year after the last dose of protocol therapy.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01678430

Contacts
Contact: Kathryn Marley +44 151 895 5287 kathryn.marley@liv.ac.uk

Locations
United Kingdom
Countess of Chester Hospital Recruiting
Chester, Cheshire, United Kingdom
Principal Investigator: Salaheddin Tueger         
Derriford Hospital Recruiting
Plymouth, Devon, United Kingdom
Principal Investigator: Simon Rule         
Torbay Hospital Recruiting
Torquay, Devon, United Kingdom
Principal Investigator: Deborah Turner         
Royal Bournemouth Hospital Recruiting
Bournemouth, Dorset, United Kingdom
Principal Investigator: Helen McCarthy         
Dorset County Hospital Recruiting
Dorchester, Dorset, United Kingdom
Principal Investigator: Akeel Moosa         
Colchester General Hospital Recruiting
Colchester, Essex, United Kingdom
Principal Investigator: Mike Hamblin         
Basingstoke and North Hampshire Hospital Recruiting
Basingstoke, Hampshire, United Kingdom
Principal Investigator: Sylwia Simpson         
Southampton General Hospital Recruiting
Southampton, Hampshire, United Kingdom
Principal Investigator: Andrew Duncombe         
Barnet and Chase Farm Hospitals Recruiting
Enfield, Hertfordshire, United Kingdom
Principal Investigator: Andres Virchis         
Kent and Canterbury Hospital Recruiting
Canterbury, Kent, United Kingdom
Principal Investigator: Christopher Pocock         
Maidstone Hospital Recruiting
Maidstone, Kent, United Kingdom
Principal Investigator: Saad Rassam         
Princess Royal Hospital Recruiting
Orpington, Kent, United Kingdom
Principal Investigator: Corrine De Lord         
Queen Elizabeth Hospital Recruiting
Woolwich, London, United Kingdom
Principal Investigator: Corrine De Lord         
West Middlesex University Hospital Recruiting
Isleworth, Middlesex, United Kingdom
Principal Investigator: Magda Alobaidi         
Ealing Hospital Recruiting
Southall, Middlesex, United Kingdom
Principal Investigator: Richard Kaczmarski         
Hillingdon Hospital Recruiting
Uxbridge, Middlesex, United Kingdom
Principal Investigator: Richard Kaczmarski         
Belfast City Hospital Recruiting
Belfast, Northern Ireland, United Kingdom
Principal Investigator: Paul Kettle         
Royal United Hospital Recruiting
Bath, Somerset, United Kingdom
Principal Investigator: Christopher Knechtli         
Weston General Hospital Recruiting
Weston-super-Mare, Somerset, United Kingdom
Principal Investigator: Philip Robson         
Queens Hospital Recruiting
Burton-upon-Trent, Staffordshire, United Kingdom
Principal Investigator: Humayun Ahmad         
Queen Elizabeth Hospital Recruiting
Gateshead, Tyne and Wear, United Kingdom
Principal Investigator: Scott Marshall         
Queen Elizabeth Hospital Recruiting
Birmingham, West Midlands, United Kingdom
Principal Investigator: Paul Moss         
Bradford Royal Infirmary Recruiting
Bradford, West Yorkshire, United Kingdom
Principal Investigator: Adrian Williams         
Airdale General Hospital Recruiting
Keighley, West Yorkshire, United Kingdom
Principal Investigator: Chetan Patalappa         
St James University Hospital Recruiting
Leeds, West Yorkshire, United Kingdom
Principal Investigator: Peter Hillmen         
Salisbury District Hospital Recruiting
Salisbury, Wiltshire, United Kingdom
Principal Investigator: Jonathan Cullis         
Arrowe Park Hospital Recruiting
Upton, Wirral, United Kingdom
Principal Investigator: Ranjit Dasgupta         
Royal Liverpool Hospital Recruiting
Liverpool, United Kingdom
Principal Investigator: Andrew Pettitt         
Sponsors and Collaborators
University of Liverpool
GlaxoSmithKline
Napp Pharmaceuticals Limited
Chugai Pharma USA
  More Information

Additional Information:
ISRCTN  This link exits the ClinicalTrials.gov site

No publications provided

ClinicalTrials.gov Identifier: NCT01678430     History of Changes
Other Study ID Numbers: OMB114578, 2011-000919-22, 009988575
Study First Received: August 30, 2012
Last Updated: October 12, 2012
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by University of Liverpool:
Chronic Lymphocytic Leukaemia
Less fit
CD20 antibody
Ofatumumab
Chlorambucil
Bendamustine

Additional relevant MeSH terms:
Leukemia
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia, Lymphoid
Immune System Diseases
Immunoproliferative Disorders
Leukemia, B-Cell
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Antibodies, Monoclonal
Bendamustine
Chlorambucil
Alkylating Agents
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Immunologic Factors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses

ClinicalTrials.gov processed this record on November 23, 2014